Inactive Instrument

Highlights QSAM Biosciences, Inc.

Equities

QSAM

US74738N2027

End-of-day quote OTC Markets Other stock markets 23:00:00 01/05/2024 BST			5-day change	1st Jan Change
8.3 ^USD	+7.10%		+3.75%	+36.07%

05-03	Telix Pharmaceuticals (Us) Inc. completed the acquisition of QSAM Biosciences, Inc. from Checkmate Capital Group LLC, Strategic Planning Assets Limited and others.	CI
03-20	QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Telix Pharmaceuticals (Us) Inc. completed the acquisition of QSAM Biosciences, Inc. from Checkmate Capital Group LLC, Strategic Planning Assets Limited and others.	05-02	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Telix Pharmaceuticals Limited signed a non-binding term sheet to acquire QSAM Biosciences, Inc. for $33.1 million.	11-13	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
QSAM Biosciences, Inc. Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®	14/06/23	CI
QSAM Biosciences Expands Its Study of Cyclosam(R) in the Treatment of Bone Cancer; Opens Patient Enrollment At Key Chicago Center, Insight Hospital and Medical Center	23/05/23	CI
QSAM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
QSAM Biosciences, Inc. Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam	26/04/23	CI
QSAM Biosciences Inc. Opens Enrollment of Second Cohort of Patients in its Phase 1 Study of CycloSam®? Targeting Metastatic Bone Cancer	05/04/23	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of Cyclosam(R) Targeting Metastatic Bone Cancer	08/03/23	CI
QSAM Biosciences, Inc. Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam Targeting Metastatic Bone Cancer	28/02/23	CI
QSAM Biosciences, Inc. Recruits the Ellis Fischel Cancer Center At the University of Missouri as Clinical Trial Site to Further Expand and Advance the Study of CycloSam for Bone Cancer	22/02/23	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
QSAM Biosciences, Inc Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer	26/10/22	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
QSAM Biosciences, Inc. Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam	13/07/22	CI
QSAM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
QSAM Biosciences, Inc. Announces the First Patient Commenced Treatment in Its Clinical Trial Evaluating Cyclosam® in Patients with Metastatic Bone Cancer	28/04/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights QSAM Biosciences, Inc.

Equities

QSAM

US74738N2027

Highlights

Filters